Scarica l'app Stockscreener
24.58
2.03%
-0.51
Dopo l'orario di chiusura:
24.28
-0.30
-1.22%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ARQT Giù?
Forum
Previsione
Precedente Chiudi:
$25.09
Aprire:
$25.09
Volume 24 ore:
775.36K
Relative Volume:
0.58
Capitalizzazione di mercato:
$3.05B
Reddito:
$376.07M
Utile/perdita netta:
$-16.14M
Rapporto P/E:
-175.70
EPS:
-0.1399
Flusso di cassa netto:
$-16.31M
1 W Prestazione:
-0.12%
1M Prestazione:
+8.04%
6M Prestazione:
+13.64%
1 anno Prestazione:
+86.35%
Intervallo 1D:
$24.21
$25.33
Intervallo di 1 settimana:
$23.59
$25.47
Portata 52W:
$12.42
$31.77
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
Nome
Arcutis Biotherapeutics Inc
Settore
Industria
Telefono
805-418-5006
Indirizzo
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Compare ARQT vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
24.58 | 3.11B | 376.07M | -16.14M | -16.31M | -0.1399 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-25 | Iniziato | Goldman | Neutral |
| 2024-12-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-08-28 | Iniziato | Jefferies | Buy |
| 2024-01-03 | Aggiornamento | Mizuho | Neutral → Buy |
| 2023-10-26 | Downgrade | Mizuho | Buy → Neutral |
| 2023-10-13 | Downgrade | Goldman | Buy → Neutral |
| 2022-09-07 | Iniziato | Needham | Buy |
| 2022-03-17 | Iniziato | Goldman | Buy |
| 2021-06-30 | Iniziato | Mizuho | Buy |
| 2021-05-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-09 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-10-08 | Iniziato | Truist | Buy |
| 2020-02-25 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-02-25 | Iniziato | Cowen | Outperform |
| 2020-02-25 | Iniziato | Goldman | Neutral |
| 2020-02-25 | Iniziato | Guggenheim | Buy |
Mostra tutto
Arcutis Biotherapeutics Inc Borsa (ARQT) Ultime notizie
Arcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026 - The Manila Times
Arcutis to give business update with Q1 results after market close May 6 - Stock Titan
Needham Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $36 - Moomoo
Arcutis Biotherapeutics (ARQT) price target increased by 10.24% to 35.70 - MSN
Arcutis Biotherapeutics Targets ZORYVE Expansion, Raises 2026 Outlook and Turns Cash-Flow Positive - Yahoo Finance
Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Emerges as a High-Growth Momentum Breakout Candidate - ChartMill
(ARQT) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Arcutis (ARQT) announces long-term phase 3 data for ZORYVE cream in children - MSN
Is It Too Late To Revisit Arcutis Biotherapeutics (ARQT) After A 75% One-Year Surge? - Yahoo Finance
Arcutis Stock Up 65% as Director Sells 10,000 Shares Under 10b5-1 Plan. Here's What Investors Should Know - The Globe and Mail
Arcutis Stock Up 65% as Director Sells 10,000 Shares Under 10b5-1 Plan. Here's What Investors Should Know - The Motley Fool
How The Arcutis Biotherapeutics (ARQT) Story Is Evolving As Analysts Cluster Around US$35 Targets - Yahoo Finance
Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales - Bitget
Aberdeen Group plc Sells 88,637 Shares of Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Perpetual Ltd Sells 1,113,976 Shares of Arcutis Biotherapeutics, Inc. $ARQT - marketbeat.com
Insider Sell: Howard Welgus Sells 10,000 Shares of Arcutis Biotherapeutics Inc (ARQT) - GuruFocus
Insider Selling: Arcutis Biotherapeutics (NASDAQ:ARQT) Director Sells 10,000 Shares of Stock - marketbeat.com
Planned sale: Arcutis (ARQT) director disposes of 10,000 shares - Stock Titan
Responsive Playbooks and the ARQT Inflection - Stock Traders Daily
Arcutis Biotherapeutics, Inc.Common stock (NQ: ARQT - The Chronicle-Journal
Insider sales reported at Arcutis Biotherapeutics (NASDAQ: ARQT) — two 10,000-share disposals - Stock Titan
Analysts Are Optimistic We'll See A Profit From Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - Moomoo
Arcutis Management to Present at the 25th Annual Needham Virtual Healthcare Conference - The Manila Times
Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Up 8.7%Here's Why - MarketBeat
Zevenbergen Capital Investments LLC Acquires Shares of 418,035 Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Arcutis executives join Needham virtual health conference April 14 - Stock Titan
Tudor Investment Corp ET AL Invests $1.32 Million in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Aug Big Picture: What are the future prospects of Arcutis Biotherapeutics Inc2026 Institutional & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Arcutis presents trial data on roflumilast cream for infants By Investing.com - Investing.com Canada
Arcutis presents trial data on roflumilast cream for infants - Investing.com
Arcutis Biotherapeutics Reports Positive Phase 2 Trial Results for ZORYVE® Cream in Infants with Atopic Dermatitis - Quiver Quantitative
Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting - The Manila Times
Nearly half of infants saw eczema itch ease in 10 minutes - Stock Titan
Nordea Investment Management AB Acquires New Holdings in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
[SCHEDULE 13G/A] Arcutis Biotherapeutics, Inc. Amended Passive Investment Disclosure - Stock Titan
Silverleafe Capital Partners LLC Increases Stock Holdings in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Understanding the Setup: (ARQT) and Scalable Risk - Stock Traders Daily
Arcutis Biotherapeutics (ARQT) Valuation Check After New Pediatric ZORYVE Phase 3 Extension Data - Yahoo Finance
A Look At Arcutis Biotherapeutics (ARQT) Valuation After Recent Share Price Weakness - simplywall.st
Arcutis (ARQT) Announces Long-Term Phase 3 Data for ZORYVE Cream in Children - Insider Monkey
Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting - Bitget
Arcutis Biotherapeutics (ARQT) Unveils New Trial Data at Dermato - GuruFocus
New eczema treatment data in infants and kids set for 2026 AAD - Stock Titan
Arcutis Biotherapeutics Inc Azioni (ARQT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.69%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):